Key statistics
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | -- |
| Low | -- |
| Bid | -- |
| Offer | -- |
| Previous close | -- |
| Average volume | -- |
|---|---|
| Shares outstanding | 54.19m |
| Free float | 48.19m |
| P/E (TTM) | 4.43 |
| Market cap | 265.54m USD |
| EPS (TTM) | 1.11 USD |
--
More ▼
Announcements
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
- Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
- Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
- Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
- Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
More ▼
